Metformin use and prostate cancer risk: A meta-analysis of cohort studies


    loading  Checking for direct PDF access through Ovid

Abstract

Background:The relationship between metformin use and the risk of prostate cancer is still inconclusive. Therefore, we performed a systematic review and meta-analysis of all eligible cohort studies to evaluate a potential association of metformin use with prostate cancer risk.Methods:A comprehensive literature search was performed in PubMed and Web of Science databases through July 2018. A DerSimonian and Laird random-effects model was applied to calculate the pooled relative risk (RR) and its 95% confidence interval (CI).Results:Eighteen cohort or nested case-control studies were included in this study with a total of 52,328 cases. In a random-effect pooled analysis, metformin use was not significantly associated with the risk of prostate cancer (RR 0.97, 95% CI 0.80–1.16, P = .711). Statistically significant heterogeneity was identified among included studies (P < .001, I2 = 98.1%). Sensitivity analysis indicated that no single study dominated the pooled RR.Conclusion:The present large meta-analysis of cohort studies did not find an association between metformin use and prostate cancer risk.

    loading  Loading Related Articles